Background: In recent years, sleep apnea syndrome (SAS) has been widely considered to be a cardiovascular disease (CVD) risk factor. Although several plausible mechanisms have been put forth to explain such association in patients with SAS, oxidative stress has been suggested to play a major role. In patients with SAS, the repetitive ischemia-reperfusion state causes excessive production of oxygen free radicals and may subsequently lead to oxidative injury of various biomolecules. Due to the high prevalence of SAS in dialysis patients, this possible uremia-specific CVD risk factor may definitely need more medical attention. Methods: We, therefore, performed a case control study to investigate the relationship between oxidative stress and SAS in a group of dialysis patients, using some well-established oxidative biomarkers. Results: Our results showed that plasma nitrotyrosine, protein carbonyl and malonaldehyde levels were significantly elevated in patients with SAS. Markers of endothelial activation such as soluble CD40 ligand were also increased in this subgroup of patients. However, there was no significant difference in serum C-reactive protein levels between these groups. Conclusions: Our results indicate that patients with SAS manifest evidence for higher oxidative stress and endothelial activation. Thus, intermittent hypoxia represents a form of oxidative stress and low-grade chronic inflammatory state that may be associated with increased cardiovascular disease in these patients.

Keywords:
Oxidative stress, Hemodialysis, Sleep apnea syndrome
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.